% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Beck:300195,
author = {M. Beck and V. Blumenberg$^*$ and V. L. Bücklein and R. A.
Bundschuh and D. C. Harrer and K. Hirschbühl and J. Jung
and W. G. Kunz and K. Menhart and M. Winkelmann and I.
Yakushev and A. L. Illert and M. Eckstein and S. Völkl and
R. Claus and L. Hansmann and J. S. Hecker and T. Kuwert and
A. Mackensen and M. Subklewe$^*$ and D. Hellwig and F.
Müller},
title = {{L}iver-{FDG}-uptake augments early {PET}/{CT} prognostic
value for {CD}19-targeted {CAR}-{T} cell therapy in diffuse
large {B} cell lymphoma.},
journal = {EJNMMI Research},
volume = {15},
number = {1},
issn = {2191-219X},
address = {Heidelberg},
publisher = {Springer},
reportid = {DKFZ-2025-00672},
pages = {25},
year = {2025},
abstract = {Despite revolutionary efficacy of CD19-CAR-T cell therapy
(CAR-T) in aggressive B cell lymphoma, many patients still
relapse mostly early. In early failure, distinct drugs
support CAR-T which makes reliable and early prediction of
imminent relapse/refractoriness critical. A complete
metabolic remission (CR) on Fluor-18-Deoxyglucose (FDG)
Positron-Emission-Computed Tomography (PET) 30 days after
CAR-T (PET30) strongly predicts progression-free survival
(PFS), but still fails in a relevant proportion of patients.
We aimed to identify additional routine parameters in PET
evaluation to enhance CAR-T response prediction.Thirty
patients with aggressive B cell lymphoma treated with CAR-T
were retrospectively analyzed. Pre-CAR-T, LDH was the
strongest PFS-predictor also by multivariate analysis.
Post-CAR-T, 10 out of 14 patients $(71.4\%)$ with PET30-CR
remained in disease remission, while 12 out of 16 patients
$(75\%)$ with incomplete metabolic remission (PET30-nCR)
relapsed after CAR-T. $28.6\%$ of patients with PET30-CR
ultimately progressed. Change of liver FDG-uptake from
baseline to day30 (Delta-Liver-SUVmean) was identified as an
independent biomarker for response. PET30-nCR and a decrease
of Delta-Liver-SUVmean were associated with a high risk of
tumor progression (HR 4.79 and 3.99, respectively). The
combination of PET30 and Delta-Liver-SUVmean identified
patients at very low, at intermediate and at very high risk
of relapse (PFS not reached, 7.5 months, 1.5 months,
respectively).Additionally to PET30 metabolic remission,
longitudinal metabolic changes in Delta-Liver-SUVmean
predicted CAR-T efficiency. Our results may guide early
intervention studies aiming to enhance CAR-T particularly in
the very high-risk patients.},
keywords = {CAR T cell therapy (Other) / DLBCL (Other) / FDG PET
(Other) / Liver-SUV (Other)},
cin = {MU01},
ddc = {610},
cid = {I:(DE-He78)MU01-20160331},
pnm = {899 - ohne Topic (POF4-899)},
pid = {G:(DE-HGF)POF4-899},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:40095158},
pmc = {pmc:PMC11914545},
doi = {10.1186/s13550-025-01201-1},
url = {https://inrepo02.dkfz.de/record/300195},
}